Compositions and methods for regulating receptor clustering
AssigneeMount Sinai Hospital
InventorsJim Dennis, Michael Demetriou
Life of this patent
Estimating the term…
Loading patent…
AssigneeMount Sinai Hospital
InventorsJim Dennis, Michael Demetriou
Estimating the term…
The invention relates to isolated complexes comprising one or more galectin associated with a Mgat5 modified glycan or polylactosamine modified glycan, and isolated lectin-Mgt5 modified glycan lattice comprising an array of mulitvalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins. Methods for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces; and methods for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering are also disclosed.
An isolated complex comprising one or more galectin interacting with a Mgat5 modified glycan or polylactosamine modified glycan that is associated with receptor clustering.
An isolated lectin-Mgat5 modified glycan lattice comprising an array of multivalent interactions among lectins, Mgat5 modified glycans, polylactosamine modified glycans, and/or glycoproteins that are associated with receptor clustering.
A method for evaluating a test compound for its ability to regulate receptor clustering through glycans on cell surfaces comprising assaying for alterations of the glycans in the presence of the test compound.
A method for evaluating a compound for its ability to regulate receptor clustering through a lectin-Mgat5 modified glycan lattice comprising (a) mixing a lectin-Mgat5 modified glycan lattice, or a lectin and one or more of a Mgat5 modified glycan and polylactosamine modified glycan, and a test compound, under conditions which maintain the lattice or permit the formation of complexes between the lectin and one or more of the Mgat5 modified glycan and polylactosamine modified glycan;
A cell based assay for evaluating a test compound for its ability to regulate receptor clustering through a lectin-Mgat5 modified glycan lattice or component thereof comprising (a) providing cells with receptors whereby clustering of the receptors is regulated through a lectin-Mgat5 modified glycan lattice or one or more of a lectin, Mgat5 modified glycan, or polylactosamine glycan;
A method for regulating receptor clustering on cell surfaces comprising altering glycans on the cell surface associated with receptor clustering.
A method for regulating receptor clustering on cell surfaces, preferably T cell receptor clustering, comprising modulating Mgat5 activity, the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice, or the amount of binding or interaction of one or more components of a lectin-Mgat5 modified glycan lattice.
A method for reducing receptor clustering on a cell surface by increasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice on the cell surface.
A method for restricting T cell receptor recruitment in response to an agonist or increasing T cell activation threshold comprising increasing Mgat5 modified glycans, polylactosamine modified glycans, or galectin-Mgat5 modified glycan lattice on the surface of the cells, or enhancing the interaction between one or more components of a galectin-Mgat5 modified glycan lattice.
A method for increasing receptor clustering on a cell surface by decreasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice on the cell surface.
A method for lowering T cell activation threshold to agonists or enhancing T cell receptor clustering comprising decreasing Mgat5 modified glycans, polylactosamine modified glycans, or galectin-Mgat5 modified glycan lattice on the surface of the T cells, or dissociating galectin from such glycans or lattice thereby lowering the T cell activation threshold.
A method for treating or preventing a condition associated with decreased or increased receptor clustering or a receptor clustering defect in a subject comprising altering glycans associated with receptor clustering.
A method for treating or preventing a condition associated with decreased or increased receptor clustering, or a receptor clustering defect, comprising modulating Mgat5 activity, the amount of Mgat5 modified glycans, polylactosamine modified glycans, or lectin-Mgat5 modified glycan lattice, and/or the amount of binding or interaction of one or more components of a lectin-MgatV modified glycan lattice.
A method for treating or preventing an autoimmune disease in a subject comprising reducing T cell receptor clustering in the subject by increasing the amount of Mgat5 modified glycans, polylactosamine modified glycans, and/or lectin-Mgat5 modified glycan lattice on the surface of T cells of the subject.
A method of, and products for, diagnosing and monitoring conditions characterized by an abonormality in receptor clustering comprising assaying for differential glycosylation of the receptor.
Dependencies are inferred from the claim text.